embryonic mutant phenotypes of Egfr (Schnepp et al., 1996) . For example, beginning at blastoderm stages, vn transcripts are expressed as two broad ventro-lateral stripes in cells patterned by the Efgr. Although vn mutant embryos only exhibit weak D/V patterning defects, genetic evidence that Vn operates in Egfr signaling stems from embryos doubly mutant for null alleles of both spi and vn that exhibit more severe mutant phenotypes than spi mutant embryos alone. This finding suggests that Spi cooperates with Vn in establishing the gradient of Egfr activity during embryogenesis, thus illustrating the possibility that multiple ligands operate in concert for proper spatial and temporal activation of Egfr.
Interestingly, the embryonic phenotype of spi; vn double mutants is not as severe as the Egfr null mutant phenotype, suggesting that a basal, ligand-independent Egfr activity exists, or that a third, unknown ligand regulates Egfr during embryogenesis, or that maternally provided Spi activity masks the interaction.
The processing of Spi from an inactive to an active form is in apparent contrast to Vn and possibly Grk. Vn contains, in addition to the EGF repeat, an Ig-like domain with homology to the neuregulins and lacks a transmembrane domain (Schnepp et al., 1996) . The mechanism by which Vn is processed, if at all, is not understood. Grk encodes a potential transmembrane domain but it has not yet been determined whether Grk functions as an unprocessed, membrane-localized signal or is processed into a secreted active ligand. Collectively, the studies on the candidate Egfr ligands have revealed that one of the mechanisms by which or processing of the transmembrane form of Spi. Ectopic Egfr activity can be modulated is by the existence of expression of rho only in the ventral midline of rho mumultiple ligand activities. Diversity in the expression pattant embryos is sufficient to rescue the ectodermal deterns of these ligands as well as in the molecular mechafects observed in these animals, suggesting that Rho nisms deployed to activate them have increased the function is required in the midline where it acts nonaurepertoire of functions of this RTK.
tonomously to pattern the ventral ectoderm (Golembo et Regulation of Egfr Activity by Positive al., 1996b) . In addition, another transmembrane protein, and Negative Feedback Loops Star (S), behaves similarly to Rho in the embryonic venRecent studies on two proteins, Argos (Aos) and Rhomtral midline and may also be involved in the production boid (Rho), have provided evidence that Egfr can also be or processing of Spi (Golembo et al., 1996b) , a model regulated via two feedback loops, suggesting that Egfr that remains to be tested biochemically. itself can regulate its own set of regulators (Figure 1) . rho expression can also be regulated by Egfr. During Rho Positively Regulates Egfr Signaling. The rho gene oogenesis, rho expression in follicle cells is expanded encodes an integral membrane protein, is dynamically in ovaries in which grk gene dosage is increased (reexpressed throughout embryogenesis in a tissue-speviewed by Ray and Schupbach, 1996) . rho expression cific fashion, and exhibits a nearly identical embryonic is repressed by CF2, a zinc finger transcription factor mutant phenotype to spi. Furthermore, rho expression that is itself repressed by Egfr signaling. Therefore, in is required during development of the wing disc for forfollicle cells, a feedback loop likely exists whereby Grk mation of distal wing veins (Sturtevant et al., 1993) and activates Egfr signaling which suppresses CF2 expresduring oogenesis for cell fate specification of anterosion, thus allowing rho expression and subsequent Egfr dorsal follicle cells. Gene dosage and genetic interaction hyperactivation (Hsu et al., 1996) . (Schweitzer et al., 1995b) . In vitro, Aos can genes, including orthodenticle (otd), are expressed in interfere with Egfr activation in a manner that is both distinct D/V domains of the ventral ectoderm prior to saturable and competitive. Given these latter results and Egfr signaling. When the production of secreted Spi the fact that Aos contains an EGF domain, it is proposed along the ventral midline is increased, the expression that Aos acts as an inhibitor of Spi by directly binding pattern of otd is not displaced dorsally (Golembo et al., to Egfr (Schweitzer et al., 1995b) , a model that remains 1996b) as would be expected if a graded signal triggered to be demonstrated biochemically.
defined threshold responses. This finding suggests that Interestingly, the expression of aos is dependent upon ventral ectodermal cells are not equivalent at the time Egfr activation (Schweitzer et al., 1995b; Golembo et al., they are presented with the midline signal. Thus the 1996a). During embryogenesis, aos expression in the issue of whether the Egfr trigger acts as a morphogen ventral ectoderm is not observed in Egfr loss-of-function gradient needs to be further substantiated. mutant embryos. Conversely, in embryos where Egfr is Freeman (1996) has described a similar competition activated by ectopic expression of secreted Spi, aos between the Aos and Spi signals during eye development. expression is greatly expanded. Furthermore, two tranHe proposes that the establishment of various cell types scription factors of the ETS family, PointedP1 (PntP1) in the ommatidium invokes successive waves of recruitand Yan, affect aos expression (Gabay et al., 1996) . ment by secreted Spi and the secreted inhibitor Aos. aos is not expressed in pntP1 mutant embryos, and According to this model, active Spi is first produced by conversely, aos is expressed in cells where PntP1 is the central cells of the ommatidia (R8, R2, and R5) and ectopically expressed. Together, these results suggest this leads to the recruitment of neighboring cells (R1, R3, not only that PntP1 is sufficient to positively regulate R4, R6, and R7) as photoreceptors. As cells differentiate aos expression, but also that it is likely a direct transcripthey express Aos, which diffuses outward to prevent tional activator. In embryos mutant for Yan, a negative other cells from activating the Egfr signaling pathway. regulator of ETS transcriptional activators, aos expresIn summary, studies of Egfr signaling have identified sion in the ventral ectoderm is expanded, and in a comproteins that act either positively or negatively to reguplementary experiment, expression of an activated form late receptor activation by specific ligands. These proof Yan greatly reduces expression of aos.
teins can be transcriptionally regulated by Egfr signaling The Aos Negative Feedback Loop. The fundamental obrevealing intricate relationships between the factors that servation, that transcription of both rho and aos can be activate the receptor and these feedback loops. regulated by Egfr itself, demonstrates that this RTK can Cooperation between Egfr and Sev activate both negative and positive feedback loops (Fig- A recent report by Freeman (1996) , examining the differure 1). What is the meaning of these intricate relationentiation of the R7 photoreceptor cell, describes a situaships between activating ligands and feedback loops? tion whereby activation of two different RTKs, Egfr and While the Rho feedback loop during oogenesis requires Sev, is required for proper establishment of cell fate. further clarification, for Aos, one potential answer is proThis unique case, whereby Egfr cooperates with another vided by studies of patterning of the embryonic ventral RTK, represents yet an additional mechanism by which ectoderm as well as the ommatidia of the adult eye.
the Egfr can participate in a multitude of developmental During patterning of the embryonic ventral ectoderm, processes. high levels of Egfr activity induce the most ventral cell Sev is highly specific to the differentiation of only one fates while lowering activities induce more ventro-lateral of the eight photoreceptor cells in each ommatidium, cell fates. Golembo et al. (1996b) propose a model the R7 cell. In a sev mutant, R7 fails to differentiate whereby graded Egfr activation is established and mainand instead becomes a lens-secreting cone cell. sev is tained by competition between the activating activity of expressed transiently in 8 of the 20 cells of the ommatidSpi and the repressing activity of Aos. In the ventral ium and Sev specificity is regulated by a more localized midline, production of Spi, Rho, and S depends on Sim.
signal, the transmembrane protein Boss, which is exRho and S participate in the production or processing pressed only in R8, a cell that physically touches R7. of Spi from an inactive, membrane form to an active, In contrast to Sev, Egfr is expressed uniformly in the secreted form, which then diffuses from the midline, eye, and clones of Egfr mutant cells are not recovered presumably forming a gradient. In cells where Egfr is in the eye indicating that Egfr is required for cell survival. maximally activated (cells immediately adjacent to the To circumvent the role of Egfr in cell survival, Freeman midline), Aos is expressed and secreted, where it, like (1996) expressed a dominant negative form of Egfr (DNSpi, diffuses to form a gradient. Along the Aos diffusion Egfr) in the developing eye after completion of cell prolifgradient, competition with secreted Spi may result in eration. In this event loss of Egfr affects determination either termination or reduction of Egfr signaling, thus of all neuronal and nonneuronal cells of the ommatidia, preserving the initial graded effects of Egfr activation.
even in R7 where Sev is required. Realizing that R7 Alternatively, the capacity of Aos to block Egfr signaling development requires both Sev and Egfr, the specificity may be incomplete. Thus only in the more lateral cells, of these RTKs was tested. Interestingly, Freeman found where lower levels of Egfr activation are encountered, that overexpression of activated Egfr in R7 can bypass is Egfr signaling terminated.
the requirement for Sev, indicating that these RTKs have A second explanation that could account for the obno inherent specificities. servation that different cells fates are determined in the ventral ectoderm by distinct signaling thresholds is that Why are two RTKs required in R7 for its differentiation?
One model proposes that, following activation of Egfr Csw (Herbst et al., 1996) . Finally, if this model is correct we are left with a paradox because results of experiin R7, the sole function of Sev is to further increase the ments in the eye have argued that Sev and Egfr have level of MAPK activation in the cell. Such a scenario similar specificities. Thus, proteins such as SHP-2 may would be reminiscent of the observation in PC12 cells not contribute to RTK specificity per se but may alternathat different levels and durations of MAPK activation tively serve to facilitate or amplify signals. lead to different cell fate outcomes (Traverse et al., 1994) . Perspectives Mechanistically, both Egfr and Sev activation would be
We have discussed some of the mechanisms that can required to reach a sufficiently high level of MAPK activaregulate the activity of the Egfr in Drosophila. However, tion to trigger R7-specific genes. Since both Egfr and from studies of this receptor in other species, additional Sev appear to regulate similar downstream events, this mechanisms that modulate the activity of this protein combinatorial model would explain why upregulation have been identified and may also play a role in Egfr of Egfr activity can bypass the requirement for Sev. regulation. Among these are the regulation of RTK activFreeman argues that this is unlikely because the ity by endocytosis, control of receptor turnover, subcelstrength of RTK signaling does not appear to regulate lular localization of the RTK within the membrane, and the choice of cell fates in the eye. Instead, he favors a cross-talk with other signaling pathways. second model whereby both RTKs are required tempo-A detailed understanding of RTK regulatory mecharally in R7. According to this model, R7 differentiation nisms may have important therapeutic applications. requires two separate bursts of Ras activation, an early Many cancers are caused by misregulation of RTK pathone triggered by Egfr and a later one triggered by Sev. ways, and some of the strategies to design drugs that Role of SHP-2/Csw in RTK Signaling cure malignancies have focused on targeting drugs So far, this review has focused on the modulation of against components of the RTK conserved signaling Egfr activity at extracellular and membrane levels. In cassette, such as p21 ras . However, because these moleaddition, it is possible that specific cytoplasmic signal cules are shared by multiple RTKs, it may be difficult transducers of RTKs exist. In the case of Egfr, one such to achieve specific therapeutic effects. An alternative example may be the nonreceptor protein tyrosine phosstrategy is the design of drugs that interfere with the phatase SHP-2/Corkscrew (Csw). Csw has been impliactivities of molecules, such as Aos, Rho, and S, that cated in multiple RTK signaling pathways, including the function in modulating specific RTK signaling pathways. Tor, Egfr, and Sev pathways (Allard et al., 1996; Perkins et al., 1996) . Collectively, these studies have led to the Selected Reading proposal that Csw is an essential component of the evolutionarily conserved cassette of molecules that Allard, J.D., Chang, H.C., Herbst, R., McNeill, H., and Simon, M.A. (1996) . Development 122, 1137 Development 122, -1146 transduce signals received by RTKs (Figure 1 ). This
